Tambov

Researchers are evaluating the efficacy, safety, pharmacokinetics, and immune response to BCD-236 combined with chemotherapy in women with relapsed or metastatic triple negative breast cancer (TNBC). This Phase 2 study focuses on patients who have received at least one prior systemic therapy and whose cancer has progressed or relapsed. The study aims to better understand how this combination treatment works in later lines of therapy for this aggressive breast cancer subtype. Participants will receive BCD-236 as an intravenous infusion along with chemotherapy, which will be chosen at the investigator's discretion. The study compares this combination treatment's effects and monitors participants over time. The primary outcome measured is the overall response rate at 24 weeks after starting treatment, assessing how well tumors respond to the therapy. Throughout the study, participants will undergo tumor assessments using RECIST 1.1 criteria to measure treatment response. Eligibility requires confirmation of AXL expression in tumor cells from fresh or archival tumor samples. Patients will be monitored for safety and disease progression, with evaluations including physical exams and performance status assessments. The study includes women aged 18 to 74 years with adequate health to participate and a life expectancy of at least four months.

Researchers are evaluating three treatments for reticular leg veins, which are mainly a cosmetic concern. The study compares a 1064 nm long-pulsed Nd:YAG laser alone, a combination of this laser with sclerotherapy, and sclerotherapy alone. The goal is to find which method is most effective while minimizing side effects like long-lasting skin discoloration. Participants will be randomly assigned to one of three groups: laser treatment alone, combined laser and sclerotherapy, or sclerotherapy alone. Each group will undergo examination, photographing, and diameter measurement of the veins before receiving their assigned treatment. The study aims to assess the disappearance of reticular veins after 6 months. During the study, participants will be monitored through examinations and photographic documentation. Researchers will measure the main outcome of vein disappearance after 6 months and observe any side effects. The study includes safety monitoring to establish the advantages and disadvantages of each treatment method, helping to identify the best option for treating reticular leg veins.

Researchers are evaluating the safety and effectiveness of endovenous thermal ablation with or without vacuum evacuation for treating large saphenous veins (greater than 15 mm) in patients with varicose veins. This study addresses concerns about the risks of heat-induced thrombosis, incomplete ablation, and vein reopening associated with current endovenous laser and radiofrequency ablation methods. The goal is to see if vacuum-assisted laser ablation reduces complications and recovery time compared to standard laser ablation. Patients undergo clinical and duplex ultrasound examination standing to measure the diameters of the target veins at multiple levels. Local anesthesia is given, and the target vein is punctured to insert the fiber. One group receives laser ablation using the ELVeS Radial 2ring fiber without vacuum, while the second group uses the ELVeS Radial 2ring Pro fiber connected to a vacuum suction that removes residual blood during the procedure. The laser energy applied is calculated based on vein diameter and location. Compression stockings are worn after treatment to aid recovery. Participants are monitored for occlusion of the treated veins at one day, 2 weeks, 1 month, 3 months, and 6 months after treatment. Researchers record procedure parameters, vein diameters, and any complications. Follow-up includes clinical assessments and ultrasound to evaluate vein closure and safety. The study includes adult patients aged 18 to 90 years with varicose veins and large saphenous veins, who consent to participate and comply with study procedures.